Please Enable Images To See This
The Simplest Way to Use My 'Secret' Trading Strategy
By Dr. David Eifrig, editor, Retirement Trader
Wednesday, March 7, 2018
One of my favorite ways to invest in stocks and bonds "at a discount" is through closed-end funds.

And I'm not the only one...

Bond trader Jeffrey Gundlach once named closed-end funds as one of his favorite "no brainer" kinds of investments. And early last year, hedge fund manager Boaz Weinstein launched a new fund just to take advantage of cheap closed-end funds.

A closed-end fund doesn't have to redeem investor money... So it's more protected against abrupt shifts in investor sentiment that can crash shares of exchange-traded funds (ETFs).

Instead, the fund raises capital, and then its shares trade freely in the market at a price independent from the assets it actually holds.

Those two prices, over time, tend to move in the same direction. But the difference can get quite large. Discounts of 10% are common. And occasionally, you'll see discounts of 20% in certain assets.

In my newsletters, I've recommended a special closed-end fund. It's a "one click" way to put one of my favorite investment strategies to work in your portfolio...

----------Recommended Links---------
This could blindside you – if you're not careful...
Last year, Steve Sjuggerud helped more than 90,000 people learn how to cash in on the "Melt Up." Now, he's issued a new warning: "My most outrageous prediction is finally coming true... You may only have weeks to prepare." Click here for Steve's latest update.
IRS warns: Your identity is 'already in the hands of criminals'
They know how much money you have... your wife's name... your pet's name... and the name of the street you grew up on. The crypto technology that will stop them could be 38 times bigger than Bitcoin. And you don't need a special account to buy it. Details here.
---------------------------------

This closed-end fund uses an options strategy called a "covered call" to generate income. (As a quick reminder, selling a covered call is a strategy that focuses on generating income from a stock that you already own.)

The fund holds a diversified portfolio of 50-plus stocks, collects their dividends, benefits when their share prices rise – and uses its stocks to write near-dated covered calls, which generate even more income.

It's called the Eaton Vance Enhanced Equity Income Fund (EOI). It's trading at around a 6% discount as I write. And it's one of the easiest ways to invest in covered calls... without making a single options trade.

Covered calls work best for investors who favor current income, less risk, and steady stocks over high-growth investments.

And when you look at the numbers, the benefits of the covered-call strategy are clear.

For example, the CBOE S&P 500 BuyWrite Index tracks the results of buying the S&P 500 Index and then selling the next expiring call with a strike price just above the index's price. Right now, this index yields 4.9% compared with just 1.9% from the S&P 500.

That's more than double the yield on the very same stocks.

And the great thing about this strategy is that you can put it to work on almost any stock that you already own...

For example, say you own 100 shares of a company's stock. You like the business, but you would be willing to sell your shares at a certain price...

With a call option, you can agree to hand over your 100 shares (called the "underlying"), by a particular day (called the "expiration"), at a particular price (called the "strike price").

This is known as "selling" (and sometimes "writing") a call option.

The call buyer pays you money (called the "premium") today in order to enter the contract. He agrees to buy the stock from you at that price, but it's his option to exercise or not.

When you sell covered calls, you want your holdings to go up a little bit, but not too much.

That makes now an ideal time to learn this strategy...

The stock market took a wild ride recently. On February 5, the Dow Jones Industrial Average lost nearly 1,200 points, or about 4.6%.

A sideways-moving market... or even a market correction... is a great time to initiate a covered-call strategy. Selling covered calls lets you "earn your way out" of a position that's in the red.

So if you're worried about the market, this is a perfect time to use this strategy. It's a great way to protect your portfolio from a potential decline... and still profit from the upside in stocks.

Here's to our health, wealth, and a great retirement,

Dr. David Eifrig

P.S. Most Americans have no idea how to use this type of strategy... But I want to show you exactly how simple it is. So tomorrow night, I'm hosting a free demonstration. We're going live at 8 p.m. Eastern time to walk you through an entire trade, step by step... where you'll learn how to start collecting thousands of dollars every month. Click here for more details.
Further Reading:

"Lots of folks who sell options are focusing on the wrong ideas," Dave says. In this essay, he outlines his "common sense" approach to selling options in any kind of market – at an incredible success rate. Learn more here: 72 Winning Trades in a Row... Here's How.
 
"I love it when I can find a way to buy a dollar for 80 cents as an investor," Steve writes. Closed-end funds allow you to do just that – and he recently shared one that's trading at a huge discount. Read more here.
  Print


BIG GAINS IN REVOLUTIONARY TREATMENTS

Today's chart is more proof of our colleague Dave Eifrig's bullish call on health care stocks...
 
Dave's central idea is that the aging Baby Boomer generation will drive big gains in health care stocks. As the Boomers get older, they'll need more medicine, testing, and doctor's visits. Not only that, but they'll also live longer with the development of revolutionary drugs.
 
That's where Nektar Therapeutics (NKTR) comes in... This leading biopharmaceutical firm develops new drugs to treat illnesses like cancer, chronic pain, and auto-immune disease. The company's shares soared in November after it reported positive trial data on NKTR-214 – one of its new experimental cancer drugs. Then last month, Nektar signed a $3.6 billion deal with Bristol-Myers Squibb (BMY) to license NKTR-214. The announcement kicked off another big rally in NKTR shares...
 
As you can see below, shares have surged since November. They're up nearly 600% since this time last year... and just hit a new all-time high. Nektar has an exciting pipeline of new cancer treatments... And as it signs new deals, its shares will likely continue to thrive...
 

Own one of Dave's favorite foreign markets with a single click...
 
Most investors are wondering where to put their money after last month's correction. Dave likes the idea of investing outside the U.S. And this country is one of his favorite markets...
 
 
Are You a
New Subscriber?

If you have recently subscribed to a Stansberry Research publication and are unsure about why you are receiving the DailyWealth (or any of our other free e-letters), click here for a full explanation...
 

Advertisement

"EVERYONE should learn my low-risk trading strategy to start collecting $1,000s every month," Doc says. "It's leaving money on the table if you're not!" Learn it here, FREE.


recent articles

How to 'Call' the Markets Correctly
By Dr. Steve Sjuggerud
Tuesday, March 6, 2018
 
What I'd like to share with you today is my big secret... It's how I've correctly called the U.S. stock market since 2009.
 
Uh-Oh...
By Dr. Steve Sjuggerud
Monday, March 5, 2018
 
The trade started in late 2016. It worked all the way through 2017. I thought we had a few more years left. But... well... uh-oh...
 
The Bears Are Wrong About This 'World Dominator' Today
By Justin Brill
Saturday, March 3, 2018
 
It's been a tough couple of weeks for this retail giant's shareholders...
 
This Strategy Crushed Buy-and-Hold... Here's How to Use It Now
By Ben Morris
Friday, March 2, 2018
 
Today, I'm sharing one of the most important stock market studies you'll see all year...
 
Double-Digit Upside Ahead for U.S. Stocks
By Brett Eversole
Thursday, March 1, 2018
 
The Dow is only a few percentage points away from new highs today. And history says it should reach them soon...
 


Home | About Us | Resources | Archive | Free Reports | Privacy Policy
To unsubscribe from DailyWealth and any associated external offers, click here.

Copyright 2018 Stansberry Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This e-letter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry Research, LLC., 1125 N Charles St, Baltimore, MD 21201

LEGAL DISCLAIMER: This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility. Stansberry Research expressly forbids its writers from having a financial interest in any security they recommend to our subscribers. And all Stansberry Research (and affiliated companies) employees and agents must wait 24 hours after an initial trade recommendation is published on the Internet, or 72 hours after a direct mail publication is sent, before acting on that recommendation.

You're receiving this email at newsletter@newslettercollector.com. If you have any questions about your subscription, or would like to change your email settings, please contact Stansberry Research at (888) 261-2693 Monday – Friday between 9:00 AM and 5:00 PM Eastern Time. Or if calling internationally, please call 443-839-0986. Stansberry Research, 1125 N Charles St, Baltimore, MD 21201, USA.

If you wish to contact us, please do not reply to this message but instead go to info@stansberrycustomerservice.com. Replies to this message will not be read or responded to. The law prohibits us from giving individual and personal investment advice. We are unable to respond to emails and phone calls requesting that type of information.